These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 30385174)

  • 1. Intestinal fibrosis.
    Lenti MV; Di Sabatino A
    Mol Aspects Med; 2019 Feb; 65():100-109. PubMed ID: 30385174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in intestinal fibrosis.
    Lenti MV; Santacroce G; Broglio G; Rossi CM; Di Sabatino A
    Mol Aspects Med; 2024 Apr; 96():101251. PubMed ID: 38359700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities.
    Frangogiannis NG
    Mol Aspects Med; 2019 Feb; 65():70-99. PubMed ID: 30056242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Fibroblast Activation Protein Restores a Balanced Extracellular Matrix and Reduces Fibrosis in Crohn's Disease Strictures Ex Vivo.
    Truffi M; Sorrentino L; Monieri M; Fociani P; Mazzucchelli S; Bonzini M; Zerbi P; Sampietro GM; Di Sabatino A; Corsi F
    Inflamm Bowel Dis; 2018 Jan; 24(2):332-345. PubMed ID: 29361086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications.
    Weiskirchen R; Weiskirchen S; Tacke F
    Mol Aspects Med; 2019 Feb; 65():2-15. PubMed ID: 29958900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Featured Article: TGF-β1 dominates extracellular matrix rigidity for inducing differentiation of human cardiac fibroblasts to myofibroblasts.
    Cho N; Razipour SE; McCain ML
    Exp Biol Med (Maywood); 2018 Apr; 243(7):601-612. PubMed ID: 29504479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Fibrotic Diseases: Current Challenges in Fibrosis Research.
    Rosenbloom J; Macarak E; Piera-Velazquez S; Jimenez SA
    Methods Mol Biol; 2017; 1627():1-23. PubMed ID: 28836191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The fate of myofibroblasts during the development of fibrosis in Crohn's disease.
    Li C; Kuemmerle JF
    J Dig Dis; 2020 Jun; 21(6):326-331. PubMed ID: 32092217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular and molecular mechanisms of intestinal fibrosis.
    Speca S; Giusti I; Rieder F; Latella G
    World J Gastroenterol; 2012 Jul; 18(28):3635-61. PubMed ID: 22851857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease.
    McKaig BC; McWilliams D; Watson SA; Mahida YR
    Am J Pathol; 2003 Apr; 162(4):1355-60. PubMed ID: 12651627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of initiation and progression of intestinal fibrosis in IBD.
    Latella G; Di Gregorio J; Flati V; Rieder F; Lawrance IC
    Scand J Gastroenterol; 2015 Jan; 50(1):53-65. PubMed ID: 25523556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases.
    Pardali E; Sanchez-Duffhues G; Gomez-Puerto MC; Ten Dijke P
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29039786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease.
    Kramann R; DiRocco DP; Humphreys BD
    J Pathol; 2013 Nov; 231(3):273-89. PubMed ID: 24006178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms that mediate the development of fibrosis in patients with Crohn's disease.
    Li C; Kuemmerle JF
    Inflamm Bowel Dis; 2014 Jul; 20(7):1250-8. PubMed ID: 24831560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues.
    Parola M; Pinzani M
    Mol Aspects Med; 2019 Feb; 65():37-55. PubMed ID: 30213667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of fibrotic changes by the synergistic effects of cytokines, dimensionality and matrix: Towards the development of an in vitro human dermal hypertrophic scar model.
    Chawla S; Ghosh S
    Acta Biomater; 2018 Mar; 69():131-145. PubMed ID: 29330036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct contribution of epithelium to organ fibrosis: epithelial-mesenchymal transition.
    Guarino M; Tosoni A; Nebuloni M
    Hum Pathol; 2009 Oct; 40(10):1365-76. PubMed ID: 19695676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can we prevent, reduce or reverse intestinal fibrosis in IBD?
    Latella G; Sferra R; Speca S; Vetuschi A; Gaudio E
    Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1283-304. PubMed ID: 23740440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic aspects and therapeutic avenues of intestinal fibrosis in Crohn's disease.
    Zorzi F; Calabrese E; Monteleone G
    Clin Sci (Lond); 2015 Dec; 129(12):1107-13. PubMed ID: 26494636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibiting Interleukin 36 Receptor Signaling Reduces Fibrosis in Mice With Chronic Intestinal Inflammation.
    Scheibe K; Kersten C; Schmied A; Vieth M; Primbs T; Carlé B; Knieling F; Claussen J; Klimowicz AC; Zheng J; Baum P; Meyer S; Schürmann S; Friedrich O; Waldner MJ; Rath T; Wirtz S; Kollias G; Ekici AB; Atreya R; Raymond EL; Mbow ML; Neurath MF; Neufert C
    Gastroenterology; 2019 Mar; 156(4):1082-1097.e11. PubMed ID: 30452921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.